Zydus Lifesciences informs about press release

03 Oct 2022 Evaluate
Zydus Lifesciences has informed that it enclosed a copy of press release dated October 3, 2022 titled - Zydus receives final approval from USFDA and 180 days shared exclusivity for Mirabegron Extended-Release Tablets.

The above information is a part of company’s filings submitted to BSE.

Zydus Lifesciences Share Price

886.75 -6.70 (-0.75%)
28-Jan-2026 10:13 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1619.20
Dr. Reddys Lab 1230.10
Cipla 1321.50
Zydus Lifesciences 886.75
Lupin 2129.75
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×